[MEN I (multiple endocrine neoplasia): patient screening and new tumor markers].
Multiple endocrine neoplasia type I (men I) associates hyperparathyroidism with pancreatic tumors. The evaluation included the patient and its family, periodically. A good patient medical history, biochemical blood tests, carried out regularly and in an organised fashion, brings to the fore the diagnosis without difficulties. Tumoral markers are now being considered an important test for diagnosis and follow-up (gastrin, pancreatic peptid, prolactin...). The newest chromogranin is a polypeptidic group which increases in the blood of patients with endocrine neoplasias (including hyperparathyroidism and tumors of pancreatic islet cells). The specific neural enolase is increase in pancreatic islet cells tumor. The evaluation of S-100 substance, 7-B2 protein, neurotensin, alpha sub-unit of chorionic gonadothrophin and other markers will soon be of help in the diagnosis of men I.
Alarcón Alacio
J
J
González González
M C
MC
López de la Torre Casares
M
M
Moreno Esteban
B
B
D014408:Biomarkers, Tumor / Q000097:blood*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D003937:Diagnosis, Differential; D006801:Humans; D008722:Methods; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis*; D010751:Phosphopyruvate Hydratase / Q000097:blood
D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D010751:Phosphopyruvate Hydratase
MEN I: Screening de pacientes y nuevos marcadores tumorales.